21Shares Solana ETF 8-K

What Happened
21Shares US LLC (the Sponsor) filed an 8‑K (Item 1.02) saying it gave CF Benchmarks Ltd. notice on June 30, 2026 that it will terminate the Pricing Benchmark Licensing Agreement effective August 31, 2026. The Pricing Benchmark is the CME CF Solana‑Dollar Reference Rate — New York Variant, which CF Benchmarks calculates and which the Trust uses to value shares daily and to calculate net asset value (NAV). The Sponsor said this termination is part of a broader transition to a new benchmark provider and intends to enter into a license with FTSE International Limited on or about August 24, 2026.

Key Details

• Sponsor: 21Shares US LLC; Fund: 21Shares Solana ETF (TSOL).
• Termination notice given: June 30, 2026; termination effective: August 31, 2026.
• Benchmark being replaced: CME CF Solana‑Dollar Reference Rate - New York Variant (administered by CF Benchmarks).
• New provider planned: FTSE International Limited license expected on/around August 24, 2026; license terms described as non‑exclusive, non‑transferable, non‑sublicensable, perpetual, worldwide with a one‑year initial term and automatic annual renewals.
• CF Benchmarks and FTSE are unaffiliated with the Sponsor.

Why It Matters
The Pricing Benchmark is used to value the ETF’s shares and to calculate the Trust’s NAV every day, so changing benchmark providers is an operationally important move. The filing indicates a planned transition with overlapping dates (FTSE license expected before the CF Benchmarks termination) and does not disclose changes to fees or fund strategy. Investors should note the provider change and monitor fund notices for any updates about methodology, calculations, or timing that could affect intraday pricing or NAV reporting.